Manufacturing: Page 8
-
Permission granted by Johnson & Johnson
Vaccine factories churn out millions more doses, speeding US rollout of coronavirus shots
The U.S. is now averaging more than 2 million doses given each day, a pace that will help President Joe Biden meet his target of 100 million shots in 100 days well ahead of schedule.
By Ned Pagliarulo • March 11, 2021 -
Merck to help J&J make vaccine doses in White House-brokered deal
The U.S. government will give Merck $269 million to help the drugmaker retool two of its facilities to make J&J's one-dose shot.
By Jonathan Gardner • Updated March 2, 2021 -
Moderna, Pfizer ready multi-pronged plans for coronavirus variants
Moderna has delivered a modified version of its vaccine to NIH scientists, while Pfizer has begun testing of an additional booster shot in a clinical trial, both precautionary steps against emerging strains.
By Jonathan Gardner , Ben Fidler • Updated Feb. 25, 2021 -
Pfizer set to double weekly production of coronavirus vaccine
The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday.
By Ned Pagliarulo • Feb. 19, 2021 -
Courtesy of BioNTech
US secures 200 million more vaccine doses from Pfizer, Moderna
With the orders now finalized, President Biden said the U.S. would have enough doses to vaccinate 300 million Americans by the end of the July.
By Ned Pagliarulo • Feb. 12, 2021 -
Moderna planning to add doses to coronavirus vaccine vials
The biotech aims to add five more vaccine doses to each vial — currently labeled to hold 10 each — but needs to secure FDA sign-off on the change.
By Ben Fidler • Feb. 2, 2021 -
Bayer agrees to help CureVac produce coronavirus vaccine
Already a partner on the shot's development, Bayer will chip in on manufacturing too, pledging to make 160 million doses in 2022.
By Ned Pagliarulo • Feb. 1, 2021 -
Novartis joins Sanofi in aiding manufacture of coronavirus vaccines
A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments.
By Ben Fidler • Jan. 29, 2021 -
Courtesy of BioNTech
US to order 200M more doses of Pfizer, Moderna coronavirus vaccines
As coronavirus variants spread, the White House aims to up U.S. vaccine supply by exercising purchase options in contracts with Pfizer and Moderna.
By Kristin Jensen • Jan. 27, 2021 -
Shutterstock.com/totojang1977
Sponsored by Medidata, a Dassault Systèmes companyCOVID-19 study builds at pandemic speed
How to accelerate time-to-market, gain greater control of study data and execution, and optimize the entire trial lifecycle.
Jan. 25, 2021 -
Getty Images
Sponsored by SGSSurface plasmon resonance in biopharmaceutical industry: Real-time and label-free characterization
Surface Plasmon Resonance (SPR) is a robust, but complex analytical tool that provides paramount value to the development and understanding biopharmaceutical products.
By Dr. Sasmit S. Deshmukh and Dr. Alex Perieteanu • Jan. 4, 2021 -
Getty Images
Sponsored by AltasciencesAltasciences' comprehensive, integrated solution for clinical supply manufacture
Integrated CRO/CDMO solutions for accelerated and more efficient early drug development programs.
Dec. 7, 2020 -
Vaccine production in focus as Moderna, Pfizer await FDA decision
Moncef Slaoui, a leader of Operation Warp Speed, said he expects 100 million Americans to be vaccinated by the end of February — an ambitious target even as Moderna and Pfizer ramp up manufacturing.
By Ned Pagliarulo • Dec. 4, 2020 -
Courtesy of Eli Lilly
US buys another 650,000 doses of Lilly's COVID-19 drug as outbreak surges
The U.S. government has ramped up spending on Lilly's and Regeneron's antibody-based COVID-19 treatments, but each remain in short supply.
By Kristin Jensen • Dec. 3, 2020 -
Getty Images
Sponsored by ZSCell therapy commercialization: How to achieve positive customer experience
What are the critical needs your commercial model must address to deliver a best-in-class experience?
By Curt Kugel, Sankalp Sethi and Meghan McDonald • Dec. 3, 2020 -
Permission granted by BioNTech SE
CDC panel recommends giving first coronavirus vaccines to healthcare workers, nursing home residents
Advisers on the CDC panel cited risk and disease burden as reasons for setting their priority list for the first vaccine doses to become available, supply of which will be extremely limited.
By Jonathan Gardner • Dec. 1, 2020 -
Bluebird faces delay for sickle cell gene therapy as rivals inch closer
The setback for Bluebird's LentiGlobin comes amid a string of manufacturing-related delays for gene therapy developers.
By Kristin Jensen • Nov. 5, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49535193876/in/album-72157713108522106/.
Chinese biotech partnered with GSK gets funding boost for coronavirus vaccine
Clover Biopharmaceuticals, one of several China-based groups advancing a coronavirus shot, has now received one of the largest investments to date from the vaccine development alliance group CEPI.
By Kristin Jensen • Nov. 3, 2020 -
Axovant shares sink on manufacturing delay for Parkinson's gene therapy
A longer-than-expected timeline for developing a new manufacturing process means a key study for Axovant's top gene therapy likely won't begin until 2022.
By Ned Pagliarulo • Oct. 30, 2020 -
Novartis, Molecular Partners partner to develop a scalable COVID-19 drug
The two Swiss firms will develop protein drugs that are meant to have similar effects as coronavirus antibodies, but would be easier to mass produce.
By Ben Fidler • Oct. 28, 2020 -
Courtesy of Eli Lilly
Lilly hires consultant to help fix issues at COVID-19 drug manufacturing plant
The New Jersey facility that ran afoul of FDA manufacturing standards is one of several Lilly is using to produce coronavirus antibody drugs.
By Kristin Jensen • Oct. 22, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Roche joins the COVID-19 antiviral drug race, betting $350M on a startup
A deal with Atea Pharmaceuticals gives Roche rights to an oral antiviral for coronavirus disease that would compete with emerging therapies from Pfizer and Merck.
By Ben Fidler • Oct. 22, 2020 -
An Indiana startup aims to join the US drug manufacturing push
Incog BioPharma Services has become the latest entity to sprout up as part of a concerted U.S. effort to onshore production of pharmaceuticals.
By Kristin Jensen • Oct. 21, 2020 -
Fujifilm to help Lilly make COVID-19 antibody drug
Lilly has asked the FDA for emergency clearance of the therapy, although a study safety review and an unrelated manufacturing inspection could complicate the request.
By Ned Pagliarulo • Oct. 15, 2020 -
Permission granted by Gilead Sciences
EU stocks up on coronavirus vaccine, drug supplies with J&J and Gilead deals
Agreements with the companies will help the EU catch up with the U.S. and the U.K. in securing advance stores of in-demand treatments.
By Kristin Jensen • Oct. 8, 2020
Previous
